Exhibit 10.26
BIOMIMETIC
--------------------------------------------------------------------------------
THERAPEUTICS
December 21, 2005
Mary Jane Helenek, R.Ph., M.S., M.B.A.
President and CEO
Luitpold Pharmaceuticals, Inc.
One Luitpold Drive
Shirley, NY 11967
Re:
Transfer Price Adjustment for
GEM 21S(R) Growth-factor Enhanced Matrix
Dear Mary Jane:
In accordance with Section 4.3 of our December 9, 2003
Manufacturing and Supply
Agreement ("MSA") and the ongoing discussions with which we have
had, effective
immediately with the next shipment received the price of the
Licensed Products
under our MSA is hereby adjusted to ** per Unit for 2006 (ie no
additional
increase for 2006). In addition, BioMimetic agrees to provide
Luitpold with a
volume discount that will apply to purchases made after **. In view
of the
upcoming holidays, we will provide you with a specific proposal
regarding the
volume discount shortly after the first of the year.
In addition, BioMimetic agrees to use its best efforts to:
(1) work with Luitpold to reach an agreem
